Source: Virtual Congress 2020 – ALERT: Pneumothorax, cough, PAH, alveolar proteinosis
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Hoeper (Hannover, Germany), H. Ghofrani (Giessen, Germany), H. Al-Hiti (Prague, Czech Republic), R. Benza (Columbus, OH, United States of America), S. Chang (Seoul, Republic of Korea), P. Corris (Newcastle upon Tyne, United Kingdom), S. Gibbs (London, United Kingdom), E. Grünig (Heidelberg, Germany), P. Jansa (Prague, Czech Republic), J. Klinger (Providence, RI, United States of America), D. Langleben (Montreal, QC, Canada), V. Mclaughlin (Ann Arbor, MI, United States of America), G. Meyer (Porto Alegre, Brazil), J. Ota-Arakaki (São Paulo, Brazil), A. Peacock (Glasgow, United Kingdom), T. Pulido (Mexico City, Mexico), S. Rosenkranz (Cologne, Germany), D. Vizza (Rome, Italy), A. Vonk-Noordegraaf (Amsterdam, Netherlands), J. White (Rochester, NY, United States of America), M. Chang (Berlin, Germany), F. Kleinjung (Berlin, Germany), C. Meier (Berlin, Germany), K. Paraschin (São Paulo, Brazil), G. Simonneau (Le Kremlin-Bicêtre, France). Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study. 3802

Member's Comments

No comment yet.

Related content which might interest you: Switching from PDE5i to riociguat in patients with PAH: A responder analysis from REPLACE Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Late Breaking Abstract - Efficacy and safety of macitentan in portopulmonary hypertension: the PORTICO trial Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Late Breaking Abstract - Efficacy of DPP1 inhibition with brensocatib in subgroups of patients with bronchiectasis- the WILLOW study Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020 Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Late Breaking Abstract - Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - Real-world evidence of dual bronchodilator therapy using Clinical COPD Questionnaire in 4700 COPD patients Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 Late Breaking Abstract - COVID-19 in patients with pulmonary hypertension: a national prospective cohort study Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Late Breaking Abstract - Effects of long-term Tobramycin Inhalation Solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. The BATTLE Randomized Controlled Trial Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020 Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - Tocilizumab in hospitalized patients with severe COVID-19: an open label, prospective study Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Late Breaking Abstract - Tocilizumab administration for the treatment of hospitalised patients with COVID-19: A systematic review and meta-analysis Source: Virtual Congress 2021 – Challenges of COVID-19 management at short and long-term Year: 2021 Late Breaking Abstract - Dry Powder Inhaler Preference in asthma patients. Results of the DPI PREFER Study Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020 Late Breaking Abstract - Comparative Effectiveness of Anti-IL5/5R Versus Anti-IgE in Patients Eligible for Both (FIRE) Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Late Breaking Abstract - RECEIVER trial: sustained use and improved outcomes with digitally supported COPD co-management Source: Virtual Congress 2021 – E-health for COVID-19 Year: 2021 Late Breaking Abstract - Identification of patients with COPD who benefit from benralizumab Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019 Late Breaking Abstract - Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021